Loading…
The agreement involves Jupiter's patented ALA-002 formulation with PharmAla.
Jupiter Neurosciences, Inc. (Nasdaq: JUNS) and PharmAla have entered into a definitive license agreement for Jupiter's patented, non-racemic MDMA formulation ALA-002. The agreement was executed to facilitate the development and commercialization of the formulation.
The terms of the agreement include specific licensing rights granted to PharmAla for the use of ALA-002. Jupiter Neurosciences retains certain rights under the agreement, ensuring continued involvement in the formulation's progress.
Jupiter Neurosciences has a free float of 221,243 shares and 770,081 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.